APOM and Cognitive impairment: Subsequently, the correlations between plasma ApoM and its derived indicators with clinical characteristics (i.e., cognitive impairment and ADL) and representative blood biomarkers (i.e., p-tau217 and NfL) of AD were analyzed, respectively.